UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):December 14, 2001
BIOJECT MEDICAL TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
| | | | |
Oregon (State or other jurisdiction of incorporation) | | 0-15360 (Commission File Number) | | 93-1099680 (IRS Employer Identification No.) |
| | |
7620 S.W. Bridgeport Road, Portland, OR (Address of principal executive offices) | | 97224 (Zip Code) |
Registrant’s telephone number, including area code:(503) 639-7221
No Change
(Former name or former address, if changed since last report)
Item 5. Other Events
Attached to this Form 8-K as Exhibit 99.1 and incorporated into this Form 8-K by reference is the company’s press release dated December 14, 2001 announcing a settlement agreement with Elan Corporation plc.
Item 7. Financial Statements and Exhibits
(c) Exhibits.
99.1 Press release dated December 14, 2001.
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: December 14, 2001.
| | |
| | BIOJECT MEDICAL TECHNOLOGIES, INC. |
|
|
|
|
| | |
|
|
|
|
| | |
|
|
|
|
| | |
|
|
|
|
| | |
|
|
|
|
| | |
|
|
|
|
| | By:/s/Christine M. Farrell |
| |
|
| | Christine M. Farrell |
|
|
|
|
| | Controller and Secretary |
2
EXHIBIT INDEX
| | |
Exhibit | | Description |
| |
|
99.1 | | Press release dated December 14, 2001. |